Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.

NCT04681131 is registered in ClinicalTrials.gov with BioAtla, Inc. as lead sponsor.

NCT NCT04681131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04681131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
Lead sponsor
BioAtla, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 17, 2021
Completion date
July 9, 2025
Enrollment
85 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer